Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature - PubMed (original) (raw)
. 2012 Feb 2;119(5):1283-91.
doi: 10.1182/blood-2011-08-374363. Epub 2011 Dec 6.
Genevieve A Secker, Yajuan J Liu, Jill A Rosenfeld, Robert S Wildin, Jennifer Cuellar-Rodriguez, Amy P Hsu, Sarah Dyack, Conrad V Fernandez, Chan-Eng Chong, Milena Babic, Peter G Bardy, Akiko Shimamura, Michael Y Zhang, Tom Walsh, Steven M Holland, Dennis D Hickstein, Marshall S Horwitz, Christopher N Hahn, Hamish S Scott, Natasha L Harvey
Affiliations
- PMID: 22147895
- PMCID: PMC3277359
- DOI: 10.1182/blood-2011-08-374363
Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature
Jan Kazenwadel et al. Blood. 2012.
Abstract
Recent work has established that heterozygous germline GATA2 mutations predispose carriers to familial myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), "MonoMAC" syndrome, and DCML deficiency. Here, we describe a previously unreported MDS family carrying a missense GATA2 mutation (p.Thr354Met), one patient with MDS/AML carrying a frameshift GATA2 mutation (p.Leu332Thrfs*53), another with MDS harboring a GATA2 splice site mutation, and 3 patients exhibiting MDS or MDS/AML who have large deletions encompassing the GATA2 locus. Intriguingly, 2 MDS/AML or "MonoMAC" syndrome patients with GATA2 deletions and one with a frameshift mutation also have primary lymphedema. Primary lymphedema occurs as a result of aberrations in the development and/or function of lymphatic vessels, spurring us to investigate whether GATA2 plays a role in the lymphatic vasculature. We demonstrate here that GATA2 protein is present at high levels in lymphatic vessel valves and that GATA2 controls the expression of genes important for programming lymphatic valve development. Our data expand the phenotypes associated with germline GATA2 mutations to include predisposition to primary lymphedema and suggest that complete haploinsufficiency or loss of function of GATA2, rather than missense mutations, is the key predisposing factor for lymphedema onset. Moreover, we reveal a crucial role for GATA2 in lymphatic vascular development.
Figures
Figure 1
Gata2 mRNA and protein levels are elevated in primary embryonic mouse LECs. (A) Quantification of Gata2 mRNA expression levels assessed by real-time RT-PCR in primary dermal LECs and BECs. Error bars represent mean ± SD of 3 replicates, and data are representative of 3 independent cell isolations from 20 to 30 embryos. (B) Primary dermal LECs and BECs cultured for 3 days on fibronectin and immunostained with CD31 (green), Prox1 (red), and Gata2 (cyan). Scale bar represents 30 μm. (C) Quantification of miR-451 expression levels assessed by real-time RT-PCR in primary dermal LECs and BECs. Error bars represent mean ± SD of 3 replicates, and data are representative of 3 independent cell isolations from 20 to 30 embryos. *P < .05 (Student paired t test).
Figure 2
Localization of Gata2 in the lymphatic vasculature. E16.5 (A-B) and adult (C-D) skin immunostained with anti-CD31 (green), Prox1 (red), and Gata2 (cyan) antibodies. Arrows indicate Gata2 localization in lymphatic vascular valves; and arrowheads, Gata2-positive hematopoietic cells. Boxed regions in panels A and C are shown at higher magnification in panels B and D, respectively. Scale bars represent 30 μm (A,C), 10 μm (B), and 15 μm (D).
Figure 3
Gata2 target genes are down-regulated after siRNA knockdown of Gata2. (A) Gata2 mRNA and protein levels are substantially reduced in primary embryonic LECs after transfection with Gata2 siRNA, compared with transfection with control siRNA. (B) Quantification of Kdr, Pecam1, Foxc2, Nfatc1, Angpt, and Itga9 mRNA expression levels by real-time RT-PCR in primary LECs transfected with control and Gata2 siRNA. (C) Prox1 mRNA and protein levels are substantially reduced in primary embryonic LECs after transfection with Gata2 siRNA, compared with transfection with control siRNA that has no established targets. Error bars represent mean ± SEM (n = 3), and data are representative of 3 independent cell isolations from 20 to 30 embryos. *P < .05 (Student paired t test). Quantification of protein levels was calculated after normalization with respect to β-actin and expressed as percentage change from controls. Each lane contains equal amounts of protein pooled from 3 separate transfections.
Figure 4
A model of Gata2 regulated transcription in LECs. Our data demonstrate that GATA2 regulates the expression of key transcription factors important for valve development. GATA2 lies upstream of Prox1, Foxc2, and Nfatc1. FoxC2 and NFATc1 have been demonstrated to interact together to coordinately regulate transcription in LECs. NFATc1 and Gata2 have been found to heterodimerize in myocytes, suggesting that these transcription factors might interact together in LECs. Gata2, Prox1, FoxC2, and NFATc1 have been demonstrated to bind the promoter and/or regulate the transcription of genes, including Pecam1, Kdr, Cdh5, Angpt2, and Itga9.
Similar articles
- GATA2 is required for lymphatic vessel valve development and maintenance.
Kazenwadel J, Betterman KL, Chong CE, Stokes PH, Lee YK, Secker GA, Agalarov Y, Demir CS, Lawrence DM, Sutton DL, Tabruyn SP, Miura N, Salminen M, Petrova TV, Matthews JM, Hahn CN, Scott HS, Harvey NL. Kazenwadel J, et al. J Clin Invest. 2015 Aug 3;125(8):2979-94. doi: 10.1172/JCI78888. Epub 2015 Jul 27. J Clin Invest. 2015. PMID: 26214525 Free PMC article. - GATA2 mutations lead to MDS and AML.
Hyde RK, Liu PP. Hyde RK, et al. Nat Genet. 2011 Sep 28;43(10):926-7. doi: 10.1038/ng.949. Nat Genet. 2011. PMID: 21956389 No abstract available. - High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.
Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachée-Chardin M, Mansat-De Mas V, Corre J, Récher C, Plat G, Bachelerie F, Donadieu J, Delabesse E. Pasquet M, et al. Blood. 2013 Jan 31;121(5):822-9. doi: 10.1182/blood-2012-08-447367. Epub 2012 Dec 6. Blood. 2013. PMID: 23223431 Free PMC article. Clinical Trial. - Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature.
Gao J, Gentzler RD, Timms AE, Horwitz MS, Frankfurt O, Altman JK, Peterson LC. Gao J, et al. J Hematol Oncol. 2014 Apr 22;7:36. doi: 10.1186/1756-8722-7-36. J Hematol Oncol. 2014. PMID: 24754962 Free PMC article. Review. - Successful umbilical cord blood hematopoietic stem cell transplantation in pediatric patients with MDS/AML associated with underlying GATA2 mutations: two case reports and review of literature.
Mallhi K, Dix DB, Niederhoffer KY, Armstrong L, Rozmus J. Mallhi K, et al. Pediatr Transplant. 2016 Nov;20(7):1004-1007. doi: 10.1111/petr.12764. Epub 2016 Jul 15. Pediatr Transplant. 2016. PMID: 27416790 Review.
Cited by
- 2q33 Deletions Underlying Syndromic and Non-syndromic CTLA4 Deficiency.
Brakta C, Tabet AC, Puel M, Pacault M, Stolzenberg MC, Goudet C, Merger M, Reumaux H, Lambert N, Alioua N, Malan V, Hanein S, Dupin-Deguine D, Treiner E, Lefèvre G, Farhat MM, Luca LE, Hureaux M, Li H, Chelloug N, Dehak R, Boussion S, Ouachée-Chardin M, Schleinitz N, Abou Chahla W, Barlogis V, Vély F, Oksenhendler E, Quartier P, Pasquet M, Suarez F, Bustamante J, Neven B, Picard C, Rieux-Laucat F, Lévy J, Rosain J. Brakta C, et al. J Clin Immunol. 2024 Nov 23;45(1):46. doi: 10.1007/s10875-024-01831-5. J Clin Immunol. 2024. PMID: 39578275 - Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.
Fekrvand S, Abolhassani H, Esfahani ZH, Fard NNG, Amiri M, Salehi H, Almasi-Hashiani A, Saeedi-Boroujeni A, Fathi N, Mohtashami M, Razavi A, Heidari A, Azizi G, Khanmohammadi S, Ahangarzadeh M, Saleki K, Hassanpour G, Rezaei N, Yazdani R. Fekrvand S, et al. J Clin Immunol. 2024 Oct 28;45(1):34. doi: 10.1007/s10875-024-01810-w. J Clin Immunol. 2024. PMID: 39466473 - CDMPred: a tool for predicting cancer driver missense mutations with high-quality passenger mutations.
Wang L, Sun H, Yue Z, Xia J, Li X. Wang L, et al. PeerJ. 2024 Sep 6;12:e17991. doi: 10.7717/peerj.17991. eCollection 2024. PeerJ. 2024. PMID: 39253604 Free PMC article. - Lymphatic System Development and Function.
Janardhan HP, Wachter BT, Trivedi CM. Janardhan HP, et al. Curr Cardiol Rep. 2024 Nov;26(11):1209-1219. doi: 10.1007/s11886-024-02120-8. Epub 2024 Aug 22. Curr Cardiol Rep. 2024. PMID: 39172295 Review. - Endothelial cell transitions in zebrafish vascular development.
Phng LK, Hogan BM. Phng LK, et al. Dev Growth Differ. 2024 Aug;66(6):357-368. doi: 10.1111/dgd.12938. Epub 2024 Jul 27. Dev Growth Differ. 2024. PMID: 39072708 Free PMC article. Review.
References
- Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371(6494):221–226. - PubMed
- Rodrigues NP, Janzen V, Forkert R, et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood. 2005;106(2):477–484. - PubMed
- Charles MA, Saunders TL, Wood WM, et al. Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. Mol Endocrinol. 2006;20(6):1366–1377. - PubMed
- Kala K, Haugas M, Lillevali K, et al. Gata2 is a tissue-specific post-mitotic selector gene for midbrain GABAergic neurons. Development. 2009;136(2):253–262. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA015704/CA/NCI NIH HHS/United States
- T32GM007266/GM/NIGMS NIH HHS/United States
- R01DK058161/DK/NIDDK NIH HHS/United States
- R01 DK058161/DK/NIDDK NIH HHS/United States
- T32 GM007266/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous